SCHEMBL8434852

SCHEMBL8434852

CNS(=O)(=O)c1ccc(C=C(C(=O)OC)C2=C(C)Cc3ccc(F)cc32)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PTGS2 P35354 3/20 0.36
▸ AKR1C2 P52895 2/20 0.35
▸ AKR1C1 Q04828 2/20 0.35
▸ AKR1C3 P42330 1/20 0.35
▸ MAPT P10636 2/20 0.32
▸ METAP2 P50579 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ EDNRA P25101 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ PMP22 Q01453 1/20 0.32
▸ HIF1A Q16665 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5138929 0.90 AKR1C3 (0.43) MEN1GAARAB9AKMT2APTGS2
SCHEMBL10739997 0.89 CA1 (0.39) PTGS2AKR1C2AKR1C1
SCHEMBL8430293 0.88 MIF (0.39) MEN1KMT2AAKR1C3LMNASMN1; SMN2
SCHEMBL8430248 0.85 CES2 (0.35) MEN1KMT2AMAPTCYP1A2NPSR1
SCHEMBL8430753 0.79 AKR1C2 (0.43) GAAAKR1C2AKR1C1AKR1C3MAPT
SCHEMBL2219869 0.79 AKR1C3 (0.57) PTGS2AKR1C2AKR1C1AKR1C3MAPT
SCHEMBL8521003 0.78 PTGS2 (0.45) PTGS2AKR1C2AKR1C1AKR1C3
SCHEMBL10603244 0.77 CA2 (0.46) ALDH1A1
SCHEMBL10736372 0.76 ALDH1A1 (0.41) GAAAKR1C3MAPTTSHRALDH1A1
SCHEMBL8428502 0.73 PTGS2 (0.38) MEN1KMT2APTGS2AKR1C2AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5965619-A ADMINISTERING AN INDENE DERIVATIVE OF GIVEN FORMULA, SUCH AS 1-(2,4,6-TRIMETHOXYBENZYLIDENE)-5-DIMETHYLAMINO-2-METHYL-3-INDENYL ACETIC ACID, TO TREAT PRECANCEROUS LESIONS SUCH AS COLONIC ADENOMATOUS POLYPS; SIDE EFFECT REDUCTION CELL PATHWAYS INC. (US) 1999-10-12 — — US disclosed
US-4656190-A PLATELET ACTIVATING FACTOR MERCK & CO., INC. (US) 1987-04-07 — — US disclosed
EP-0142801-A2 Indene derivatives useful as paf-antagonists MERCK & CO. INC. (US) 1985-05-29 — — EP disclosed
Send feedback